Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HDM1010
- Development stage
- Unknown
- Lead developer
- Huadong Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HDM1010 is an oral fixed-dose combination tablet developed by Huadong Medicine for type 2 diabetes mellitus. It combines HDM1002, an orally active, potent, highly selective small-molecule full agonist of the glucagon-like peptide 1 receptor, with an undisclosed sodium-glucose cotransporter 2 inhibitor. The combination is intended to provide complementary glucose-lowering activity through GLP-1 receptor activation and inhibition of renal glucose reabsorption via SGLT2. The US FDA cleared its investigational new drug application in June 2025, enabling Phase 1 clinical development in the United States.
02
Targets
Beyond the preview
Go deeper on HDM1010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HDM1010.